Kiniksa Pharmaceuticals shares are trading higher after Wedbush maintained its Outperform rating on the stock and raised its price target fr
Kiniksa Pharmaceuticals shares are trading higher after Wedbush maintained its Outperform rating on the stock and raised its price target from $59 to $72.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.